This study aimed to investigate the expression profiles and clinical relevance of additional protein biomarkers in A-GFAP-A.<h4>Methods</h4>A total of 19 patients with A-GFAP-A, 28 patients with neuromyelitis optica spectrum disorder (NMOSD), 12 patients with non-inflammatory neurological diseases (NINDC), and 12 healthy controls (HC) were enrolled. The gene discussed is GFAP; the disease is neuromyelitis optica.